Lymphatic filariasis


Several gaps remain in understanding the “elimination” of lymphatic filariasis and identifying the most efficient strategies to help countries achieve this target. The following issues have been prioritized:

  • evaluating new combinations of quality-assured essential medicines for use in MDA and frequencies of distribution, which are more effective than and as safe as current regimens;

  • modelling potential new MDA regimens to estimate long-term efficacy and number of rounds required to meet elimination targets;

  • developing new programmatic tools to plan, implement and monitor distribution of preventive chemotherapy for the purpose of enhancing coverage of MDA;

  • devising standardized, cost–effective strategies for post-elimination surveillance including new diagnostic tests to measure infection and exposure in both humans and vectors;

  • formulating efficient strategies to quantify the number of lymphoedema and hydrocele patients at subnational level;

  • developing new medicines or treatment regimens to reverse or stop progression of clinical disease;

  • advocating sustained MDA and MMDP in countries where these interventions are already being implemented and starting them in countries where they have not yet been introduced.
Courtesy of Indonesia and GSK

Photo Gallery


You are watching: "Lymphatic Filariasis Elimination Program: Alleviating Suffering, Ending Shame"
The Carter Center

Learn about the disease

In order to view files in .wmv format, you will need Windows Media Player 9, Streaming mode. Multimedia help


Media contact:
Ashok Moloo
+41 22 791 1637
+41 79 540 50 86 (mobile)